Northern Trust Corp Anavex Life Sciences Corp. Transaction History

Northern Trust Corp

  • $690 Billion
  • Q4 2024

A detailed history of Northern Trust Corp transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Northern Trust Corp holds 706,901 shares of AVXL stock, worth $5.95 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
706,901
Previous 695,963 1.57%
Holding current value
$5.95 Million
Previous $3.95 Million 92.06%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025
BUY
$5.11 - $12.56 $55,893 - $137,381
10,938 Added 1.57%
706,901 $7.59 Million
Q3 2024

Nov 13, 2024
BUY
$4.11 - $7.04 $110,176 - $188,721
26,807 Added 4.01%
695,963 $3.95 Million
Q2 2024

Aug 14, 2024
SELL
$3.39 - $5.02 $168,140 - $248,986
-49,599 Reduced 6.9%
669,156 $2.82 Million
Q1 2024

May 14, 2024
SELL
$4.55 - $6.75 $103,148 - $153,022
-22,670 Reduced 3.06%
718,755 $3.66 Million
Q4 2023

Feb 13, 2024
SELL
$5.04 - $9.95 $50,107 - $98,922
-9,942 Reduced 1.32%
741,425 $6.9 Million
Q3 2023

Nov 13, 2023
BUY
$6.55 - $9.37 $100,732 - $144,101
15,379 Added 2.09%
751,367 $4.92 Million
Q2 2023

Aug 11, 2023
BUY
$7.66 - $9.5 $68,786 - $85,310
8,980 Added 1.24%
735,988 $5.98 Million
Q1 2023

May 15, 2023
SELL
$8.32 - $11.75 $1,422 - $2,009
-171 Reduced 0.02%
727,008 $6.23 Million
Q4 2022

Feb 13, 2023
BUY
$7.65 - $14.43 $92,327 - $174,155
12,069 Added 1.69%
727,179 $6.73 Million
Q3 2022

Nov 14, 2022
BUY
$8.9 - $12.86 $27,162 - $39,248
3,052 Added 0.43%
715,110 $7.38 Million
Q2 2022

Aug 12, 2022
BUY
$7.31 - $12.84 $168,027 - $295,140
22,986 Added 3.34%
712,058 $7.13 Million
Q1 2022

May 13, 2022
SELL
$9.74 - $17.69 $169,563 - $307,965
-17,409 Reduced 2.46%
689,072 $8.48 Million
Q4 2021

Feb 08, 2022
BUY
$16.88 - $23.31 $398,790 - $550,698
23,625 Added 3.46%
706,481 $12.3 Million
Q3 2021

Nov 15, 2021
SELL
$16.82 - $25.75 $120,750 - $184,859
-7,179 Reduced 1.04%
682,856 $12.3 Million
Q2 2021

Aug 13, 2021
BUY
$10.16 - $28.86 $371,236 - $1.05 Million
36,539 Added 5.59%
690,035 $15.8 Million
Q1 2021

May 12, 2021
SELL
$5.17 - $16.13 $294 - $919
-57 Reduced 0.01%
653,496 $9.77 Million
Q4 2020

Feb 11, 2021
SELL
$4.01 - $7.58 $44,899 - $84,873
-11,197 Reduced 1.68%
653,553 $3.53 Million
Q3 2020

Nov 16, 2020
SELL
$3.8 - $5.0 $19,957 - $26,260
-5,252 Reduced 0.78%
664,750 $3.03 Million
Q2 2020

Aug 14, 2020
BUY
$2.62 - $5.2 $135,309 - $268,554
51,645 Added 8.35%
670,002 $3.3 Million
Q1 2020

May 14, 2020
BUY
$2.38 - $5.81 $164,453 - $401,459
69,098 Added 12.58%
618,357 $1.95 Million
Q4 2019

Feb 14, 2020
BUY
$2.31 - $3.14 $82,060 - $111,545
35,524 Added 6.91%
549,259 $1.42 Million
Q3 2019

Nov 13, 2019
BUY
$2.22 - $3.9 $813,163 - $1.43 Million
366,290 Added 248.42%
513,735 $1.62 Million
Q2 2019

Aug 13, 2019
BUY
$2.75 - $3.7 $99,200 - $133,470
36,073 Added 32.39%
147,445 $497,000
Q1 2019

May 13, 2019
SELL
$1.68 - $3.42 $204 - $417
-122 Reduced 0.11%
111,372 $339,000
Q4 2018

Feb 12, 2019
SELL
$1.25 - $2.75 $606 - $1,333
-485 Reduced 0.43%
111,494 $174,000
Q2 2018

Aug 14, 2018
SELL
$2.08 - $4.26 $702,586 - $1.44 Million
-337,782 Reduced 75.1%
111,979 $293,000
Q1 2018

May 09, 2018
BUY
$2.32 - $3.44 $61,700 - $91,486
26,595 Added 6.28%
449,761 $1.24 Million
Q4 2017

Feb 14, 2018
SELL
$3.12 - $4.94 $13,041 - $20,649
-4,180 Reduced 0.98%
423,166 $1.36 Million
Q3 2017

Nov 13, 2017
BUY
$3.42 - $4.87 $1.46 Million - $2.08 Million
427,346
427,346 $1.77 Million

Others Institutions Holding AVXL

# of Institutions
188
Shares Held
29.2M
Call Options Held
894K
Put Options Held
821K
View Full List

About ANAVEX LIFE SCIENCES CORP.

AVXL Quotes by TradingView
  • Ticker AVXL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,942,800
  • Market Cap $655M
  • Description
  • Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...
More about AVXL
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email